PMC:3598541 / 198-1760 JSONTXT

{"project":"NEUROSES","denotations":[{"id":"T23","span":{"begin":563,"end":578},"obj":"CHEBI_6887"},{"id":"T24","span":{"begin":862,"end":877},"obj":"CHEBI_6887"},{"id":"T26","span":{"begin":671,"end":676},"obj":"PATO_0001177"},{"id":"T28","span":{"begin":38,"end":43},"obj":"PATO_0000389"},{"id":"T29","span":{"begin":459,"end":464},"obj":"PATO_0000389"},{"id":"T30","span":{"begin":607,"end":612},"obj":"PATO_0000389"},{"id":"T31","span":{"begin":760,"end":765},"obj":"PATO_0000389"},{"id":"T32","span":{"begin":140,"end":147},"obj":"PATO_0000502"},{"id":"T33","span":{"begin":265,"end":275},"obj":"PATO_0000076"},{"id":"T34","span":{"begin":475,"end":482},"obj":"PATO_0000467"},{"id":"T35","span":{"begin":773,"end":777},"obj":"PATO_0000384"},{"id":"T36","span":{"begin":773,"end":777},"obj":"CHEBI_30780"},{"id":"T37","span":{"begin":782,"end":788},"obj":"PATO_0000383"},{"id":"T38","span":{"begin":997,"end":1002},"obj":"PATO_0000309"},{"id":"T39","span":{"begin":1291,"end":1294},"obj":"CHEBI_73494"},{"id":"T40","span":{"begin":1476,"end":1480},"obj":"PATO_0000610"},{"id":"T61","span":{"begin":38,"end":43},"obj":"PATO_0000389"},{"id":"T81","span":{"begin":265,"end":275},"obj":"PATO_0000076"}],"text":"Background\nTreatment of patients with acute mania remains a considerable medical challenge since onset of action of antimanic medication is delayed for several days. Psychostimulants could have an earlier onset of action. This assumption is based on the ‘vigilance regulation model of mania’ which postulates that vigilance is unstable in manic patients. Accordingly, vigilance-stabilising psychostimulants could be more useful than conventional treatment in acute mania. We present here the study protocol of a trial intended to study the efficacy and safety of methylphenidate in the initial treatment of acute mania.\n\nMethods/design\nA multi-centre, randomised, double-blind, placebo-controlled clinical trial will be conducted in 88 bipolar inpatients with acute mania. Male and female patients older than 18 years will be randomised to treatment with either methylphenidate (20 to 40 mg/day) or placebo for 2.5 days, given once or twice daily. The main outcome measure is the reduction in the Young Mania Rating Scale (YMRS) after 2.5 days of treatment. Other outcome measures include the Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) the Clinical Global Impression–Bipolar Scale (CGI-BP), the Screen for Cognitive Impairment in Psychiatry (SCIP), actigraphy and the EEG-‘Vigilance Algorithm Leipzig’ (VIGALL).\n\nDiscussion\nA positive study outcome of the proposed study could substantially impact our understanding of the etiopathogenesis of mania and open new treatment perspectives.\n\nTrial registration\nClinicalTrials.gov: NCT 01541605 "}